Waubant E, Vukusic S, Gignoux L, Dubief F Durand, Achiti I, Blanc S, Renoux C, Confavreux C
UCSF MS Center, San Francisco, CA 94117, USA.
Neurology. 2003 Jul 22;61(2):184-9. doi: 10.1212/01.wnl.0000078888.07196.0b.
To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders.
Data on all patients who received IFNB who were entered in the prospective European Database for Multiple Sclerosis (EDMUS) database in Lyon as of March 31, 2001, were reviewed. Responders were defined as having a lower relapse rate on IFNB compared with the year or 2 years prior to IFNB therapy.
Two hundred sixty-two patients with relapsing MS received at least 6 months of IFNB: 200 relapsing remitting (RR) and 62 relapsing secondary progressive (SP). One-third of patients experienced a higher or identical annual relapse rate while on IFNB treatment. Compared with nonresponders, responders were older and had longer disease duration at the time IFNB was initiated. RRMS responders also had a higher relapse rate during the year prior to IFNB therapy and SPMS responders had a higher Disability Status Scale score at initiation of IFNB.
Clinical profiles of patients with relapsing MS who respond to IFNB may differ from those who do not with a more inflammatory and less neurodegenerative disease at the time IFNB is initiated.
确定对干扰素-β（IFNB）治疗有反应的多发性硬化症（MS）患者的比例，并评估IFNB反应者与无反应者的临床特征是否存在差异。
回顾了截至2001年3月31日录入里昂前瞻性欧洲多发性硬化症数据库（EDMUS）的所有接受IFNB治疗患者的数据。反应者的定义为与IFNB治疗前一年或两年相比，接受IFNB治疗时复发率较低。
262例复发型MS患者接受了至少6个月的IFNB治疗：200例复发缓解型（RR）和62例继发进展型（SP）。三分之一的患者在接受IFNB治疗期间年复发率较高或相同。与无反应者相比，反应者年龄更大，在开始使用IFNB时疾病持续时间更长。RRMS反应者在IFNB治疗前一年的复发率也更高，SPMS反应者在开始使用IFNB时残疾状态量表评分更高。
对IFNB有反应的复发型MS患者的临床特征可能与无反应者不同，在开始使用IFNB时炎症反应更强，神经退行性变更轻。
